Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-01

Study Completion Date

2025-11-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomized, double-blind, placebo-controlled, single ascending dose clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IGNX001 in peanut-allergic adults and older Adolescents.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety and Efficacy Study of Xolair in Peanut Allergy

NCT00086606

Allergy

TERMINATED PHASE2

Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy

NCT04950504

Peanut Allergy

TERMINATED PHASE1

Oral Peanut Immunotherapy

NCT01324401

Peanut Allergy

COMPLETED NA

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

NCT01781637

Peanut Allergy Food Allergy

COMPLETED PHASE1/PHASE2

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

NCT05621317

Peanut Allergy Peanut Hypersensitivity Peanut-Induced Anaphylaxis +1 more

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peanut Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, double-blind, placebo-controlled, single ascending dose study with single blind sentinel period

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

With the exception of the single sentinel participants for each cohort who will be single blinded (participant blinded), the study will be designed as a double-blind study thus the Investigator, site staff (other than pharmacists), sponsor, sponsors delegates (if applicable) and participants are all blinded to treatment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IGNX001

Participants will receive IGNX001 given as a single subcutaneous dose on Day 1.

Group Type EXPERIMENTAL

IGNX001

Intervention Type DRUG

IGNX001 given as a single subcutaneous dose on Day 1.

Placebo

Participants will receive IGNX001 placebo given as a single subcutaneous dose on Day 1.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo to IGNX001 given as a single subcutaneous dose on Day 1.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IGNX001

IGNX001 given as a single subcutaneous dose on Day 1.

Intervention Type DRUG

Placebo

Placebo to IGNX001 given as a single subcutaneous dose on Day 1.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* History of physician-diagnosed peanut allergy with clinical reaction to peanut within 2 hours of exposure to peanut or peanut-containing food (within the last 15 years).
* Peanut specific IgE level ≥ 1 kUA/L.
* Positive peanut SPT with wheal diameter ≥ 5 mm.

Exclusion Criteria

* History of severe or life-threatening anaphylaxis requiring intubation or admission to intensive care unit within 1 year prior to Screening.
* Current, or within the past year, treatment with food allergen immunotherapy or participation in a food allergy immunotherapy study.
* Current treatment with aeroallergen immunotherapy, except if on stable monthly maintenance SC aeroallergen immunotherapy.

Minimum Eligible Age

15 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No